Eigen RadarEconomics
Analysis

Gufic raises profit as operating cash inflow shrinks

India’s Gufic Biosciences increased consolidated revenue and profit from continuing operations for July–September. Half-year earnings also rose, but operating cash inflow after tax declined as inventories and receivables absorbed funds. The pharmaceuticals company reported fixed-asset payments, borrowing flows and a closing cash balance in the same interim results.

Economics & Markets··Midday
In the cleanroom of an Indian injectable-medicines plant, a gowned operator loads a tray of glass vials into a newly installed stainless-steel freeze dryer, with racks crowded with waiting trays behind.

Pharmaceutical earnings rise

India’s pharmaceuticals company Gufic Biosciences reported higher revenue and net profit for July–September. The consolidated results approved on November 14 cover the quarter ended September 30. The group reports its activities within a single pharmaceuticals segment.[1], [2]

Quarterly operating revenue increased from 23,705.45 lakh Indian rupees to 28,827.30 lakh rupees. One lakh equals 100,000 rupees. Profit from continuing operations rose from 1,682.26 lakh rupees to 2,346.86 lakh rupees. Half-year revenue was 54,909.10 lakh rupees, with profit from continuing operations of 4,578.14 lakh rupees.[1]

Operating cash inflow contracts

April–September operating cash inflow after tax declined from 5,911.52 lakh rupees to 516.69 lakh rupees. Inventory movements absorbed 4,773.96 lakh rupees, while trade and other receivables absorbed 3,002.16 lakh rupees. Payments for fixed assets and capital advances were 3,595.16 lakh rupees. Net investing cash outflow reached 4,280.96 lakh rupees.[1]

Financing supplies 4,068.83 lakh rupees

Financing activities generated 4,068.83 lakh rupees. This included net current borrowing inflows of 7,706.43 lakh rupees and non-current borrowing repayments of 1,277.17 lakh rupees. Closing cash and equivalents stood at 6,523.04 lakh rupees. Independent auditors carried out a limited review of the interim results.[1]

References

  1. News sourceGufic BiosciencesGufic raises profit while operating cash inflow contracts↩1↩2↩3↩4
  2. News sourceUnivestGufic Biosciences reported higher quarterly profit↩